SCHEMBL8310787

SCHEMBL8310787

CNc1ccc(Cl)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 3/20 0.49
HDAC6 Q9UBN7 1/20 0.49
SRC P12931 1/20 0.45
ALDH1A1 P00352 3/20 0.44
MAOB P27338 3/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SUV39H2 Q9H5I1 1/20 0.43
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42
FLT1 P17948 1/20 0.42
KDR P35968 1/20 0.42
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
DYRK1A Q13627 1/20 0.41
MAOA P21397 1/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092356 0.83 MAPT (0.56) GRM4ALDH1A1MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL7416456 0.82 NPC1 (0.57) GRM4ALDH1A1MAPTMEN1KMT2A
SCHEMBL4133738 0.82 NPC1 (0.48) GRM4HDAC6SRCALDH1A1MAOB
SCHEMBL4202030 0.81 MAPK1 (0.40) GRM4HDAC6SRCALDH1A1MAOB
SCHEMBL1576262 0.80 CA2 (0.52) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL10984450 0.80 GRM4 (0.47) GRM4HDAC6SRCALDH1A1MAOB
Hydrochloric Acid SCHEMBL7008397 0.80 MAPT (0.53) GRM4ALDH1A1MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL3661738 0.80 NPC1 (0.47) GRM4HDAC6SRCALDH1A1MAOB
Bromide SCHEMBL20984091 0.80 NPC1 (0.47) GRM4HDAC6SRCALDH1A1MAOB
SCHEMBL21892023 0.79 PGK1 (0.50) GRM4HDAC6ALDH1A1MAOBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117466803-A Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2024-01-30 CN disclosed
CN-111132976-B Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2023-08-22 CN disclosed
EP-3154634-B1 IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE UNIV LILLE (FR) 2021-02-24 EP disclosed
CN-111793068-A Heteroaryl compounds and uses thereof 西建卡尔有限责任公司 2020-10-20 CN disclosed
CN-105307657-B Heteroaryl compounds and uses thereof 西建卡尔有限责任公司 2020-07-10 CN disclosed
CN-111132976-A Compounds, salts thereof and methods for treating diseases 阿卡蒂亚药品公司 2020-05-08 CN disclosed
US-10323016-B2 Imidazol- or 1,2,4-triazol-derivatives and their use UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2019-06-18 US disclosed
US-20170190687-A1 IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE Université de Lille (FR) 2017-07-06 US disclosed
EP-3154634-A1 IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE Université de Lille 2 Droit et Santé (FR) 2017-04-19 EP disclosed
WO-2015189330-A1 IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2015-12-17 WO disclosed
US-7566786-B2 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2009-07-28 US disclosed
EP-1944305-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-16 EP disclosed
EP-1633748-B1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LTD (GB) 2008-03-05 EP disclosed
US-7329660-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2008-02-12 US disclosed
US-7329660-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2008-02-12 US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190687-A1 IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE CYP3A43, CYP51A1, CYP3A7 GRM4 4353/4885HDAC6 60/4885SRC 1740/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A GRM4 2670/4885HDAC6 447/4885SRC 3938/4885
US-10323016-B2 Imidazol- or 1,2,4-triazol-derivatives and their use CYP3A43, CYP51A1, CYP3A7 GRM4 4353/4885HDAC6 60/4885SRC 1740/4885
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A GRM4 2670/4885HDAC6 447/4885SRC 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.